Staar Surgical Company has evolved to become a developer, manufacturer and global distributor of products used by ophthalmologists and other eye care professionals to improve or correct vision in patients suffering from refractive conditions, cataracts and glaucoma.
| Revenue (Most Recent Fiscal Year) | $239.44M |
| Net Income (Most Recent Fiscal Year) | $-80.45M |
| PE Ratio (Current Year Earnings Estimate) | 61.20 |
| PE Ratio (Trailing 12 Months) | 43.35 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 3.98 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.47 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | 1.70% |
| Net Margin (Trailing 12 Months) | 0.16% |
| Return on Equity (Trailing 12 Months) | 8.43% |
| Return on Assets (Trailing 12 Months) | 6.50% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.68 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.08 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 1.76 |
| Book Value per Share (Most Recent Fiscal Quarter) | $7.49 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.26 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.70 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.00 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Common Shares Outstanding | 50.20M |
| Free Float | 30.17M |
| Market Capitalization | $1.31B |
| Average Volume (Last 20 Days) | 0.79M |
| Beta (Past 60 Months) | 1.22 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 39.90% |
| Percentage Held By Institutions (Latest 13F Reports) | 96.70% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |